There were significantly higher numbers of circulating CD161+ CD4+ T-cells and CD161NEGCD8+ T-cells in natalizumab-treated than in untreated MS patients (Figure 3A and Figure 3E). The gene discussed is KLRB1; the disease is myeloid sarcoma.